Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Cytek Biosciences (CTKB) Gross Margin (2020 - 2026)

Cytek Biosciences filings provide 6 years of Gross Margin readings, the most recent being 52.92% for Q4 2025.

  • On a quarterly basis, Gross Margin fell 563.0% to 52.92% in Q4 2025 year-over-year; TTM through Dec 2025 was 51.84%, a 358.0% decrease, with the full-year FY2025 number at 51.84%, down 358.0% from a year prior.
  • Gross Margin hit 52.92% in Q4 2025 for Cytek Biosciences, roughly flat from 52.69% in the prior quarter.
  • In the past five years, Gross Margin ranged from a high of 66.36% in Q3 2022 to a low of 27.21% in Q4 2021.
  • Median Gross Margin over the past 5 years was 56.7% (2023), compared with a mean of 52.96%.
  • Biggest five-year swings in Gross Margin: surged 8798bps in 2022 and later crashed -974bps in 2023.
  • Cytek Biosciences' Gross Margin stood at 27.21% in 2021, then surged by 323bps to 60.77% in 2022, then fell by -7bps to 56.75% in 2023, then rose by 3bps to 58.55% in 2024, then decreased by -10bps to 52.92% in 2025.
  • The last three reported values for Gross Margin were 52.92% (Q4 2025), 52.69% (Q3 2025), and 52.34% (Q2 2025) per Business Quant data.